Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemispherx takes beating on US FDA rejection for Ampligen, again

This article was originally published in Scrip

Executive Summary

Shares of Hemispherx Biopharma plummeted nearly 20% in after-hours trading on 4 February after the company revealed the US FDA refused to approve Ampligen (rintatolimod) as a treatment for chronic fatigue syndrome – declaring in a complete response letter (CRL) the firm must conduct at least one additional clinical trial, complete various nonclinical studies and perform a number of data analyses.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC020294

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel